Multiple sensitivity analyses were supportive of clinical benefit. The most common adverse reaction in patients receiving palbociclib plus letrozole was neutropenia. This article summarizes the FDA thought process and data supporting accelerated approval based on PALOMA-1 which may be contingent upon verification and description of clinical benefit in the on-going and fully accrued confirmatory trial, PALOMA-2.
Introduction
Hormonal therapy is the standard of care in the first line metastatic breast cancer (MBC) setting for estrogen receptor (ER)-positive, HER2-negative patients without rapidly progressing visceral metastases due to its ability to control disease with minimal side effects. The hormonal agents approved in first line MBC, tamoxifen, anastrozole, and letrozole, demonstrate modest improvements in response rate and time to progression but have not clearly demonstrated an improved OS (1, 2). Unfortunately, not all patients respond to first-line hormonal therapy as they present with primary or de novo resistance, and some patients who initially respond subsequently have breast cancer progression (acquired resistance).
New therapeutic strategies have recently emerged in an attempt to improve the outcome of patients with ER-positive MBC. The cyclin D1-CDK 4/6-retinoblastoma pathway is critical for cell proliferation and its dysregulation has been implicated in breast cancer biology (3) (4) (5) . 
Nonclinical Pharmacology and Toxicology
Palbociclib is a kinase inhibitor of CDK4 and CDK6. In vitro, palbociclib reduced cellular proliferation of ER-positive breast cancer cell lines by blocking cell cycle progression from G1 to S phase. The most sensitive ER-positive cell lines had high levels of RB1 and CCND1 expression and low levels of CDKN2A expression (7) . Palbociclib combined with antiestrogens enhanced in vitro inhibition of cell proliferation in ER-positive breast cancer cells, and enhanced in vivo anti-tumor activity in ER-positive breast cancer mouse models. The combination of palbociclib and letrozole increased the inhibition of RB1 phosphorylation, and tumor growth compared to each drug alone in a patient-derived ER-positive breast cancer mouse xenograft model.
Adverse effects in the bone marrow, lymphoid tissues and male reproductive organs were seen in rats and dogs after administration of oral palbociclib at clinically relevant exposures.
Altered glucose metabolism with associated changes in the pancreas, and secondary effects in the eye, teeth, kidney, and adipose tissue were identified in rats at doses approximately 11 times the human exposure (AUC) at the therapeutic dose. Lens degeneration in the eye and chronic progressive nephropathy remained after the recovery period. Although hyperglycemia was not observed in clinical trials, appropriate monitoring is incorporated in the ongoing and planned palbociclib clinical trials.
Palbociclib was clastogenic in an in vitro micronucleus assay using Chinese Hamster Ovary cells and an in vivo rat bone marrow micronucleus assay through an aneugenic mechanism. Palbociclib can cause fetal harm based on its mechanism of action and findings in animals. Reports from rodent carcinogenicity studies were not submitted or required to support this application as the indication includes patients with advanced breast cancer.
Clinical Pharmacology
The palbociclib Cmax was observed between 6 to 12 hours following oral administration.
The mean (± SD) plasma elimination half-life was 29 hours (±5 hours), and the mean apparent oral clearance was 63.1 L/hr (29% CV). The mean absolute bioavailability of palbociclib after an oral 125 mg dose was 46%. Steady state was achieved within 8 days, with a median accumulation ratio of 2.4 (range 1.5 -4.2).
The palbociclib absorption and exposure were very low in approximately 13% of the population under the fasted condition. Food intake increased the palbociclib exposure in this small subset of the population, while not altering palbociclib exposure in the rest of the population. Consequently, food intake reduced the intersubject variability in palbociclib exposure, compared to the overnight fasted condition, which supports administration of palbociclib with food.
The human mass balance trial showed palbociclib was primarily eliminated by hepatic metabolism, and renal elimination appears to play a minor role. Based on the population pharmacokinetic analysis, a dose reduction was not needed in patients with mild or moderate renal impairment, or mild hepatic impairment. Further examination of the effects of severe renal impairment or moderate and severe hepatic impairment on the palbociclib exposure will be performed as a postmarketing requirement.
an exposure-response relationship could not be made. A greater reduction in absolute neutrophil count appears to be associated with increased palbociclib exposure.
Clinical Trial Design
The characterized by CCND1 amplification (CCND1 to CEP11 fluorescence in situ hybridization (FISH) ratio ≥1.5) and/or loss of CDKN2A (CDKN2A to CEP9 FISH ratio <0.8). This led to the addition of the biomarker-positive population. Cohort 1 included the unselected patient population (N=66) and Cohort 2 included the biomarker selected population (N=99). After an interim analysis of Cohort 1 showed a preliminary benefit, enrollment to Cohort 2 was halted and the analysis plan for the primary endpoint (PFS) was changed to include both cohorts. Initially, a total of 114 events were needed to achieve 80% power to detect an HR=0.67 with a 1-sided alpha = 0.10. The plan for the final analysis was subsequently changed from 114 events to 95 events.
In addition, there was a post-hoc significance level adjustment for the two PFS interim analyses using a gate-keeping procedure for hypotheses testing in a hierarchical approach to control the family wise error rate. Breakthrough therapy designation was granted for palbociclib based on preliminary results from PALOMA-1 reporting a substantial improvement in PFS over an existing therapy.
Demographics, Disease Characteristics, and Prior Treatment
Baseline demographics and disease characteristics were balanced between treatment groups except for misclassification of stratification factors. Site of disease was misclassified in 17 (20.2%) patients in the palbociclib plus letrozole arm and 12 (14.8%) patients in the letrozole arm which led to an imbalance of patients with visceral disease, (44%: palbociclib arm, 53%: letrozole arm) and bone only disease (20%: palbociclib arm, 15%: letrozole arm). Patients were recruited at 50 centers in 12 countries, 74% were from Europe, 22% from North America, and 4% from Asia. The median age was 63 years (range 38-89 years), the majority were Caucasian (90%), and all patients had an ECOG PS of 0 or 1. Forty-three percent of patients had received chemotherapy and 33% had received antihormonal therapy in the neoadjuvant or adjuvant setting Consistent results were observed across patient subgroups of disease-free interval, disease site, and prior therapy and did not identify a clinically defined subgroup that derived greater benefit from the addition of palbociclib. An improvement in the palbociclib plus the letrozole treatment arm was also observed when the two cohorts were analyzed separately (Table 1 and 
to patients in the letrozole arm, regardless of biomarker status. This PFS improvement was more pronounced in the biomarker unselected population. Subgroup analyses based on FISH results (biomarkers positive vs. biomarker negative) demonstrated preservation of the PFS benefit of palbociclib plus letrozole but did not identify a population that derived an improved or inferior benefit and further analysis for predictive biomarkers is warranted.
Safety Results
The safety database included 95 patients from the PALOMA-1 trial who received palbociclib at an oral daily dose of 125 mg supported by safety data from 700 patients participating in five industry sponsored completed or ongoing clinical trials. In the Phase 2 portion of PALOMA-1, 100% of patients (n=83) on the palbociclib plus letrozole arm experienced a treatment-emergent adverse event (AE) and 84% of patients (n=65/77) experienced a treatment-emergent AE on the letrozole arm. Sixty four patients (77%) on the palbociclib plus letrozole arm and sixteen patients (21%) on the letrozole alone arm experienced a Grade 3 or 4 AE. There was one death on study in the palbociclib plus letrozole arm, which was deemed a result of disease progression.
The most common (≥25%) adverse reactions were neutropenia, leukopenia, fatigue, anemia, upper respiratory infection, nausea and stomatitis. The most common (≥5%) Grade ≥3 AEs in the palbociclib plus letrozole arm were neutropenia (48% Grade 3, 6% Grade 4), leukopenia (19% Grade 3, no Grade 4), and anemia (5% Grade 3, 1% Grade 4). While febrile neutropenia events were reported in other palbociclib clinical programs, no cases were seen in PALOMA-1 and the majority of Grade ≥3 neutropenia events were managed by dose reductions and/or delays and did not require permanent discontinuation or addition of supportive therapy. Dose reductions were reported in 36% of patients receiving palbociclib. Permanent discontinuation due to an AE occurred in 8% of patients receiving palbociclib plus letrozole (neutropenia 6%, asthenia 1%, and fatigue 1%). Eighteen patients (22%) on the palbociclib plus letrozole arm experienced serious adverse events (SAEs) and five patients (7%) on the letrozole arm experienced an SAE. The most frequently reported SAEs in patients receiving palbociclib plus letrozole were pulmonary embolism (4%) and diarrhea (2%).
Discussion
The accelerated approval pathway allows for the use of surrogate endpoints and addresses added uncertainty with post-marketing trials to verify its clinical benefit (9) . The accelerated approval of palbociclib was based on a large relative and absolute improvement in PFS. This magnitude of effect represents a meaningful benefit over standard therapy for first line ERpositive, HER2-negative, MBC. Consistent results were observed across subgroups of diseasefree interval, disease site, and prior therapy, and were supported by a higher overall response rate. The safety profile of palbociclib appeared to be acceptable for the patient population and the toxicities were transient and reversible. There was an increased frequency of cytopenias (particularly neutropenia), infections, diarrhea, nausea, eye disorders, and pulmonary embolisms in palbociclib treated patients compared to those treated with letrozole alone in PALOMA-1.
However, the data provide assurance that the neutropenia can be appropriately managed using the dose modification guidance established in Cohort 1 as evidenced by a lower frequency of discontinuations due to neutropenia in the sequentially enrolled Cohort 2.
These benefits were weighed against the limitations of the study which included a small sample size, open-label design, and amendments made to the statistical analysis plan. In addition, while the BICR analysis supported the primary endpoint of PFS, censoring was high. In most instances of discrepancy, the investigator determined progressive disease, while the BICR did not confirm progressive disease by imaging. Bone lesion progression according to RECIST criteria is difficult to measure and could have accounted for the difficulty of the BICR to confirm disease progression in many of these patients. FDA reviewed the narratives and case report forms from all patients and believes that the investigator assessments were appropriate. While there was a misclassification of stratification factors resulting in an imbalance of patients with visceral disease, sensitivity analyses showed that these misclassifications did not affect the study results as the PFS analyses remained in favor of the palbociclib plus letrozole arm.
Regulatory considerations also took into account the potential for approval in a biomarker positive population. Although 73% of the patients in the study were biomarker positive, palbociclib was approved for an unselected marker population. This decision was supported by the benefit of palbociclib regardless of the biomarker status and the fact that approximately 40% of the population screened for Cohort 2 was biomarker positive. There are many mechanisms for gene over-expression and loss of expression; PALOMA-1 only examined gene amplification and deletion. Further analysis is warranted and a postmarketing commitment will seek to identify an optimal predictive biomarker.
Residual uncertainty in the magnitude of benefit in median PFS will be addressed in multiple ongoing and planned trials in both the adjuvant and advanced breast cancer settings (Table 2 ). Data from these ongoing studies did not factor into the accelerated approval decision of palbociclib as the study results were unknown. However, FDA has stated that post-marketing clinical trials to verify benefit should be well underway at the time of accelerated approval, and the fact that the confirmatory trial (PALOMA-2) was fully accrued supported the approval 
